BALTIMORE, MD--(Marketwired - Jul 22, 2013) - In a newly released research update, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a recent article on its website that biotech firms such as Nuvilex Inc. (OTCQB: NVLX) are designing more effective drug delivery methods to treat cancer.
Earlier this year, nanomedicine-based firms executed successful clinical trials and engaged in large development deals with some of the world's leading drug giants. These firms have demonstrated an ability to encapsulate potent drugs in tiny particles measuring billionths of a meter in diameter is opening up new options for super-accurate drug delivery, increasing precision hits at the site of disease with limited side effects. This is a similar concept to Nuvilex's approach where pro-drugs are encapsulated and targeted directly at the tumor with greater efficacy than traditional methods and with far less toxicity.
In July of this year, researchers at Purdue University announced that they have developed a concept to potentially improve delivery of drugs for cancer treatment using nanoparticles that concentrate and expand in the presence of higher acidity found in tumor cells.
The concept involves using nanoparticles made of "weak polybases," compounds that expand when transported into environments mimicking tumor cells, which have a higher acidity than surrounding tissues. The researchers used sophisticated modeling to show how the particles would accumulate in regions of higher acidity and remain there long enough to delivery anticancer drugs.
Whether one is referring to high-profile nanomedicine-based firms or pre-clinical university research, the fact that drug delivery is at the forefront of the fight against cancer bodes well for Nuvilex, which has already demonstrated significant efficacy and low toxicity in its Phase II inoperable pancreatic cancer trials. Moreover, it should capture the attention of new investors and prospective partners as well.
To view Nuvilex reports and articles and to view our disclaimer, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.